Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases
Arch Neurol 60:337-341, 320, Zarow,C.,et al, 2003
Clinical Features and Natural Histry of Progressive Supranuclear Palsy, A Clinical Cohort Study
Neurol 60:910-916, Nath,W.,et al, 2003
Diffusion-Weighted Imaging Discriminates Progressive Supranuclear Palsy from PD, But Not From the Parkinson Variant of Multiple System Atrophy
Neurol 60:922-927, Seppi,K.,et al, 2003
Stem Cells and Neurological Disease
JNNP 74:553-557, Barker,R.A.,et al, 2003
Randomized Trial of Pallidotomy Versus Medical Therapy for Parkinson's Disease
Ann Neurol 53:558-569, Vitek,J.L.,et al, 2003
Weight Loss in Parkinson's Disease
Ann Neurol 53:676-679, Chen,H.,et al, 2003
Parkinson Disease With Old-Age Onset
Arch Neurol 60:529-533, Diederich,N.J.,et al, 2003
Identifying the Pattern of Olfactory Deficits in Parkinson Disease Using the Brief Smell Identification Test
Arch Neurol 60:545-549, Double,K.L.,et al, 2003
Alzheimer's Disease and Parkinson's Disease
NEJM 348:1356-1364, Nussbaum,R.L. &Ellis,C.E., 2003
Acupuncture in Clinical Neurology
The Neurologist 9:137-148, Rabinstein,A.A. &Shulman,L.M., 2003
Neurologic Manifestations and Outcome of West Nile Virus Infection
JAMA 290:511-515,524,558, Sejvar,J.J.,et al, 2003
Pathological Gambling Associated with Dopamine Agonist Therapy in Parkinson's
Neurol 61:422-423, Driver-Dunckley,E.,et al, 2003
Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease
Arch Neurol 60:1059-1064,1043, Chen,H.,et al, 2003
Language Function and Dysfunction in Corticobasal Degeneration
Neurol 61:493-499, Graham,N.L.,et al, 2003
A Double-Blind Controlled Trial of Bilateral Fetal Nigral Transplantation in Parkinson's Disease
Ann Neurol 54:403-414, Olanow,C.W.,et al, 2003
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Awakenings From Persistent Vegetative State: Report of Three Cases With Parkinsonism and Brain Stem Lesions on MRI
JNNP 74:1571-1573, Matsuda,W.,et al, 2003
Five-Year Follow-up of Bilateral Stimulatioin of the Subthalamic Nucleus in Advanced Parkinson's Disease
NEJM 349:1925-1934,1888, Krack,P.,et al, 2003
Orthostatic Hypotension in De Novo Parkinson Disease
Arch Neurol 60:1400-1404, Bonuccelli,U.,et al, 2003
Disappearance of Resting Tremor After "Stereotaxic" Thalamic Stroke
Neurol 61:1014-1015, Probst-Cousin,S.,et al, 2003
Subthalamic DBS Replaces Levodopa in Parkinson's Disease
Neurol 58:396-401, Vingerhoets,F.J.G.,et al, 2002
Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease
JAMA 287:455-463,509, Hobson,D.E.,et al, 2002
Practice Parameter: Initiation of Treatment for Parkinson's Disease: An Evidence-based Review
Neurol 58:11-17, Miyasaki,J.M.,et al, 2002
Diffusion-weighted MRI Differentiates the Parkinson Variant of Multiple System Atrophy from PD
Neurol 58:575-580, Schocke,M.F.H.,et al, 2002
Donepezil for Cognitive Impairment in Parkinson's Disease: A Randomised Controlled Study
JNNP 72:708-712, Aarsland,D.,et al, 2002
Incidence and Prediction of Falls in Parkinson's Disease: A Prospecitve Multidisciplinary Study
JNNP 72:721-725, Wood,B.H.,et al, 2002
Therapies for Movement Disorders
Arch Neurol 59:699-702, Goetz,C.G &Hinson,V.K., 2002
Treatment Interventions for Parkinson's Disease: An Evidence Based Assessment
Lancet 359:1589-1598, Rascol,O.,et al, 2002
Impact of Sustained Deprenyl (Selegiline) in Levodopa-Treated Parkinson's Disease: A Randomized Placebo-Controlled Extension of the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism Trial
Ann Nuerol 51:604-612, Shoulson,I.,et al, 2002
Cholinergic Vesicular Transporters in Progressive Supranuclesar Palsy
Neurol 58:1013-1018,997, Suzuki,M.,et al, 2002
Botulinum Toxin for Cricopharyngeal Dysfunction in Parkinson's Disease
NEJM 346:1174-1175, Restivo,D.A.,et al, 2002
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Nonmotor Fluctuations in Parkinson's Disease
Neurol 59:408-413, Witjas,T.,et al, 2002
A Meta-Analysis of Coffee Drinking, Cigarette Smoking, and the Risk of Parkinson's Disease
Ann Neurol 52:276-284,261, Hernan,M.A.,et al, 2002
Intakes of Vitamins E and C, Carotenoids, Vitamin Supplements, and PD Risk
Neurol 59:1161-1169, Zhang,S.M.,et al, 2002
T2-weighted MRI Differentiates Multiple System Atrophy from Parkinson's Disease
Neurol 59;1265-1267, Kraft,E.,et al, 2002
Familial Dementia With Lewy Bodies
Arch Neurol 59:1622-1630, Tsuang,D.W.,et al, 2002
Mitochondrial Therapy for Parkinson Disease
Arch Neurol 59:1523, Rosenberg,R.N., 2002
Bilateral Subthalamic Nucleus Stimulation Improves Health-Related Quality of Life in PD
Neurol 59:1976-1978, Lagrange,E.,et al, 2002
How Valid is the Clinical Diagnosis of Parkinson's Disease in the Community?
JNNP 73:529-534, Scharg,A.,et al, 2002
Effect on Mood of Subthalamic DBS for Parkinson's Disease
Neurol 59:1427-1429, Berney,A.,et al, 2002
Mania Following Deep Brain Stimulation for Parkinson's Disease
Neurol 59:1421-1424, Kulisevsky,J.,et al, 2002
Driving Safety in Parkinson's Disease
Neurol 59:1787-1788, Zesiewicz,T.A.,et al, 2002
HIV-Related Movement Disorders, Epidemiology, Pathogenesis and Management
CNS Drugs 16:663-668, Cardoso,F., 2002
Welding-Related Parkinsonism
Neurol 56:8-13,4, Racette,B.A.,et al, 2001
Involuntary Movements After Anterior Cerebral Artery Territory Infarction
Stroke 32:258-261, Kim,J.S., 2001
Parkinsonism as the Presenting Manifestation of HIV Infection: Improvement on HAART
Neurol 56:278-279, Hersh,B.P.,et al, 2001
Functional Correlates of Pallidal Stimulation for Parkinson's Disease
Ann Neurol 49:155-164,142, Fukuda,M.,et al, 2001
Thalamic Deep Brain Stimulation
Arch Neurol 58:218-222, Ondo,W.,et al, 2001